- $2.50bn
- $2.13bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.09 | ||
| Price to Tang. Book | 7.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -114.91% | ||
| Return on Equity | -74.17% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Directors
- Frank Torti CHM (42)
- Peter Salzmann CEO (54)
- Renee Barnett CFO (42)
- Julia Butchko CTO (50)
- Mark Levine OTH (48)
- William Macias OTH (63)
- Andrew Fromkin DRC (55)
- Eric Venker DRC (34)
- Douglas Hughes IND (59)
- George Migausky IND (66)
- Atul Pande IND (67)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 6th, 2018
- Public Since
- May 14th, 2019
- No. of Shareholders
- 3
- No. of Employees
- 207
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 169,860,683
- Address
- 320 West 37Th Street, NEW YORK, 10018
- Web
- https://immunovant.com/
- Phone
- +1 9175803099
- Contact
- Chau Cheng
- Auditors
- Ernst & Young LLP
Upcoming Events for IMVT
Q1 2026 Immunovant Inc Earnings Release
Immunovant Inc Annual Shareholders Meeting
Similar to IMVT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Immunovant share price?
As of Today at 21:15 UTC, shares in Immunovant are trading at $14.72. This share price information is delayed by 15 minutes.
How has the Immunovant share price performed this year?
Shares in Immunovant last closed at $14.72 and the price had moved by -46.95% over the past 365 days. In terms of relative price strength the Immunovant share price has underperformed the S&P500 Index by -51.04% over the past year.
What are the analyst and broker recommendations for Immunovant?
The overall consensus recommendation for Immunovant is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immunovant dividend yield?
Immunovant does not currently pay a dividend.
Does Immunovant pay a dividend?
Immunovant does not currently pay a dividend.
When does Immunovant next pay dividends?
Immunovant does not currently pay a dividend.
How do I buy Immunovant shares?
To buy shares in Immunovant you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immunovant?
As of the previous close price of $14.72, shares in Immunovant had a market capitalisation of $2.50bn.
Where are Immunovant shares listed?
Here are the trading details for Immunovant:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IMVT
What kind of share is Immunovant?
Based on an overall assessment of its quality, value and momentum Immunovant is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immunovant share price forecast for 2025?
The analyst consensus target price for shares in Immunovant is $45.23. That is 207.27% above the last closing price of $14.72.
Analysts covering Immunovant currently have a consensus Earnings Per Share (EPS) forecast of -$2.79 for the next financial year.
Find out moreWhat is the trend in the Immunovant share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunovant. Over the past six months, its share price has underperformed the S&P500 Index by -48.66%.
As of the last closing price of $14.72, shares in Immunovant were trading -41.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immunovant PE Ratio?
The Immunovant PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immunovant?
Immunovant's management team is headed by:
- Frank Torti - CHM
- Peter Salzmann - CEO
- Renee Barnett - CFO
- Julia Butchko - CTO
- Mark Levine - OTH
- William Macias - OTH
- Andrew Fromkin - DRC
- Eric Venker - DRC
- Douglas Hughes - IND
- George Migausky - IND
- Atul Pande - IND